GlassScriptPhysician profile
William Henry Ennis
NPI 1245610914
$6,235.81
in general payments reported to CMS, 2019-2025
55 companies · $2,195 in 2025
The $2,195 reported for 2025 was more than what 90% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.44 · 2021: $181 · 2022: $785 · 2023: $1,434 · 2024: $1,602 · 2025: $2,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,230.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $669.69 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $453.38 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Astrazeneca Pharmaceuticals LP | $426.63 | 2022-2025 | Imfinzi, Calquence, Lynparza |
| Incyte Corporation | $412.86 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Janssen Biotech, INC. | $371.92 | 2022-2025 | Darzalex, Erleada, Carvykti |
| Novocure INC. | $279.14 | 2020-2025 | Optune, Optune Lua (Novottf-200t) |
| Genentech USA, INC. | $244.93 | 2024-2025 | Polivy, Lunsumio, Columvi |
| Novartis Pharmaceuticals Corporation | $242.68 | 2021-2025 | |
| Intuitive Surgical, INC. | $226.58 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $221.19 | 2021-2025 | Libtayo, Lynozyfic |
| Exelixis INC. | $219.48 | 2022-2025 | Cabometyx |
| Eisai INC. | $207.65 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $146.80 | 2021-2024 | Precisetumor, Myrisk |
| Sobi, INC | $134.16 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $125.56 | 2023-2025 | Ultomiris, Soliris |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $118.80 | 2023-2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $101.16 | 2022-2025 | |
| Boston Scientific Corporation | $97.45 | 2024 | |
| Daiichi Sankyo INC. | $79.95 | 2022-2025 | Datroway, Enhertu |
| Morphosys, US INC. | $79.08 | 2022-2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $78.77 | 2023-2025 | Fotivda |
| Pharmaessentia USA Corporation | $75.26 | 2023-2025 | Besremi |
| Inari Medical, INC. | $69.31 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lilly USA, LLC | $64.97 | 2022-2023 | Verzenio, Jaypirca, Retevmo |
| Blueprint Medicines Corporation | $62.44 | 2022-2024 | Ayvakit |
| Seagen INC. | $62.07 | 2022-2023 | Tukysa, Padcev |
| Beone Medicines USA, INC. | $59.16 | 2025 | Brukinsa, Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.82 | 2024-2025 | Gilotrif |
| Apellis Pharmaceuticals, INC. | $57.72 | 2023-2025 | Empaveli |
| Pfizer INC. | $56.89 | 2021-2022 | |
| Emd Serono, INC. | $56.51 | 2025 | |
| Beigene USA, INC. | $54.09 | 2023-2024 | Brukinsa |
| Puma Biotechnology, INC. | $50.13 | 2023 | Nerlynx |
| Abbvie INC. | $42.25 | 2025 | |
| Servier Pharmaceuticals LLC | $38.47 | 2024-2025 | |
| Immunogen, INC. | $36.60 | 2023-2024 | Elahere, Elahere |
| Jazz Pharmaceuticals INC. | $34.59 | 2025 | |
| Amgen INC. | $32.87 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $32.19 | 2024-2025 | Clonoseq |
| Csl Behring | $31.90 | 2025 | Hizentra |
| Astellas Pharma US INC | $30.43 | 2025 | Xtandi, Padcev |
| Genmab U.S., INC. | $30.30 | 2023 | Epkinly |
| Taiho Oncology, INC. | $29.76 | 2022-2024 | |
| Genzyme Corporation | $25.07 | 2025 | |
| Elekta, INC. | $24.89 | 2023 | Elekta Unity |
| Monteris Medical Corporation | $23.75 | 2025 | Neuroblate |
| Stemline Therapeutics INC. | $22.39 | 2023 | Orserdu |
| Celgene Corporation | $21.22 | 2023 | Pomalyst |
| Coherus Oncology, INC. | $19.98 | 2024 | |
| Accuray Incorporated | $19.61 | 2020 | |
| Rigel Pharmaceuticals, INC. | $17.68 | 2023 | Tavalisse, Rezlidhia |
| Myovant Sciences INC. | $16.19 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2024 | Augtyro |
| Fennec Pharmaceuticals, INC. | $14.08 | 2025 | Fyarro |
| Pharmacosmos Therapeutics INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.